Stay updated on Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial

Sign up to get notified when there's something new on the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Page revision updated from v3.0.1 to v3.0.2; the Back to Top element was removed.
    Difference
    0.5%
    Check dated 2025-09-14T00:47:30.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1.
    Difference
    0.5%
    Check dated 2025-09-06T21:27:44.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The web page has added a facility name and location details, while removing specific state, country, and city information. This indicates a shift towards a more generalized presentation of location data.
    Difference
    54%
    Check dated 2025-08-30T15:59:13.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.16.11 to v2.16.12.
    Difference
    0.3%
    Check dated 2025-08-16T12:55:23.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.3%
    Check dated 2025-08-09T08:14:57.000Z thumbnail image
  7. Check
    47 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.
    Difference
    4%
    Check dated 2025-08-02T04:27:00.000Z thumbnail image

Stay in the know with updates to Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page.